Compare KRYS & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRYS | CORT |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 9.7B |
| IPO Year | 2017 | 2001 |
| Metric | KRYS | CORT |
|---|---|---|
| Price | $365.80 | $91.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $297.60 | $96.50 |
| AVG Volume (30 Days) | 330.3K | ★ 975.8K |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 128.00 | N/A |
| EPS | ★ 1.83 | N/A |
| Revenue | $389,130,000.00 | ★ $761,407,000.00 |
| Revenue This Year | $38.74 | $26.08 |
| Revenue Next Year | $32.53 | $26.98 |
| P/E Ratio | $202.78 | ★ N/A |
| Revenue Growth | ★ 33.94 | 12.79 |
| 52 Week Low | $130.50 | $28.66 |
| 52 Week High | $382.54 | $95.11 |
| Indicator | KRYS | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 60.23 | 74.13 |
| Support Level | $253.89 | $76.41 |
| Resistance Level | $382.54 | N/A |
| Average True Range (ATR) | 13.26 | 3.67 |
| MACD | -1.03 | -0.17 |
| Stochastic Oscillator | 55.77 | 81.05 |
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.